Beractant
Pronouncation: (ber-ACT-ant)Class: Lung surfactant
Trade Names:
Survanta
- Suspension 25 mg phospholipids per mL suspended in 0.9% sodium chloride solution. With 0.5 to 1.75 mg triglycerides, 1.4 to 3.5 mg free fatty acids, and less than 1 mg protein per mL.
Pharmacology
 | ||||||
Feedback for Beractant
Compare with other drugs. | ||||||
Replaces deficient endogenous pulmonary surfactant and restores surface activity of lung.
Indications and Usage
Prevention and treatment (“rescue”) of neonatal respiratory distress syndrome (RDS) in premature infants.
Contraindications
Standard considerations.
Dosage and Administration
Newborns and infantsIntratracheal
Prevention25 mg/kg/instillation for 4 instillations (total dose of 100ߙmg/kg is administered in 4 quarter doses); dose is started within 15 min of birth.
Rescue25 mg/kg/instillation for 4 instillations (total dose 100 mg/kg). May be repeated for continued or progressive RDS.
General Advice
- Warm medication by allowing it to stand at room temperature for 20 min or in hand for 8 min. Do not use artificial warming methods.
- If settling has occurred, swirl gently; do not shake.
- Before administering, assure proper placement and patency of endotracheal (ET) tube. If suctioning is required, allow patient to stabilize before administering.
- Instill through small (5 Fr) catheter inserted into ET tube with tip above carina. Do not instill into main stem bronchus. Attach catheter to syringe. Fill with medication and discard any excess through catheter to ensure that total dose to be given remains in syringe. After each quarter dose, remove catheter and mechanically ventilate patient for 30 sec. Continue procedure until total dose is achieved. Administer each quarter dose with infant in different position.
- Avoid suctioning patient for 1 h after administration unless airway is obstructed.
Storage/Stability
Store unopened vials under refrigeration and protect from light. Warmed unopened vials (under 8 h) can be returned to refrigerator for future use. Drug should not be warmed and refrigerated more than once. Discard any open vials.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Intracranial hemorrhage.
Precautions
MonitorContinually monitor oxygen and carbon dioxide measurements. If oxygen saturation decreases or bradycardia develops, discontinue administration until patient is stabilized. |
Administer drug only by trained personnel in a closely supervised setting.
Nosocomial sepsis
Occurred in controlled clinical trials.
Overdosage
Symptoms
Acute airway obstruction (based on animal studies).
Patient Information
- Advise family of infant's condition and offer frequent updates.
- Encourage active family participation in care whenever possible.
- Provide emotional support; offer hospital services and support groups.
 |
Link to Page |  |
Print Page |  |
Email Page |  | Add to List |
